MetaADEDB 2.0 @ LMMD
Cysteamine
(NSKJTUFFDRENDM-UHFFFAOYSA-N)
Structure
SMILES
OC(C(C(=O)O)O)C(=O)O.NCCS
Molecular Formula:
C6H13NO6S
Molecular Weight:
227.236
Log P:
-1.5474
Hydrogen Bond Acceptor:
8
Hydrogen Bond Donor:
6
TPSA:
179.88
CAS Number(s):
27761-19-9
Synonym(s)
1.
Cysteamine
2.
Cysteinamine
3.
Mercaptamine
4.
2-Aminoethanethiol
5.
Becaptan
6.
Cystagon
7.
Cysteamine Bitartrate
8.
Cysteamine Dihydrochloride
9.
Cysteamine Hydrobromide
10.
Cysteamine Hydrochloride
11.
Cysteamine Maleate (1:1)
12.
Cysteamine Tartrate
13.
Cysteamine Tartrate (1:1)
14.
Cysteamine Tosylate
15.
Cysteamine, 35S-Labeled
16.
Mercamine
17.
Mercaptoethylamine
18.
beta-Mercaptoethylamine
19.
2 Aminoethanethiol
20.
35S-Labeled Cysteamine
21.
Bitartrate, Cysteamine
22.
Cysteamine, 35S Labeled
23.
Dihydrochloride, Cysteamine
24.
Hydrobromide, Cysteamine
25.
Hydrochloride, Cysteamine
26.
Tartrate, Cysteamine
27.
Tosylate, Cysteamine
28.
beta Mercaptoethylamine
External Link(s)
MeSHD003543
PubChem Compound90470742
24883453
23111531
ChEBI50386
CHEMBLCHEMBL2062263
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1NauseaFAERS: 16US FAERS
2VomitingFAERS: 16US FAERS
3MalaiseFAERS: 9US FAERS
4Amino acid level increasedFAERS: 4US FAERS
5HeadacheFAERS: 4US FAERS
6Abdominal PainFAERS: 3US FAERS
7Abdominal discomfortFAERS: 3US FAERS
8Completed SuicideFAERS: 3US FAERS
9Drug ineffectiveFAERS: 3US FAERS
10PneumoniaFAERS: 3US FAERS
11Cerebrovascular accidentFAERS: 2US FAERS
12DizzinessFAERS: 2US FAERS
13Nephrotic SyndromeFAERS: 2US FAERS
14PainFAERS: 2US FAERS
15Product dose omissionFAERS: 2US FAERS
16ThrombosisFAERS: 2US FAERS
17AgranulocytosisFAERS: 1US FAERS
18Arteriovenous fistula occlusionFAERS: 1US FAERS
19Blood creatine increasedFAERS: 1US FAERS
20Catheter site infectionFAERS: 1US FAERS
21Chest PainFAERS: 1US FAERS
22CystinosisFAERS: 1US FAERS
23Disease ProgressionFAERS: 1US FAERS
24Drug administration errorFAERS: 1US FAERS
25Feeling abnormalFAERS: 1US FAERS
26Gastric infectionFAERS: 1US FAERS
27Gastroenteritis norovirusFAERS: 1US FAERS
28HypotensionFAERS: 1US FAERS
29Intentional product use issueFAERS: 1US FAERS
30Investigation abnormalFAERS: 1US FAERS
31LeukopeniaFAERS: 1US FAERS
32Limb operationFAERS: 1US FAERS
33MalnutritionFAERS: 1US FAERS
34Nasal PolypsFAERS: 1US FAERS
35NasopharyngitisFAERS: 1US FAERS
36NephritisFAERS: 1US FAERS
37Noninfective encephalitisFAERS: 1US FAERS
38OverdoseFAERS: 1US FAERS
39ParaparesisFAERS: 1US FAERS
40Patient dissatisfaction with treatmentFAERS: 1US FAERS
41Product administration errorFAERS: 1US FAERS
42Product quality issueFAERS: 1US FAERS
43SwellingFAERS: 1US FAERS
44TransplantFAERS: 1US FAERS
45TremorFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120237

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.